Cardiac Arrhythmia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Na<sup>+</sup> microdomains and sparks: Role in cardiac excitation-contraction coupling and arrhythmias in ankyrin-B deficiency.
|
30731085 |
2019 |
Cardiac Arrhythmia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
ANK2 p.Q1283H is a disease-associated variant that confers susceptibility to stress-induced arrhythmias, which may be prevented by the administration of metoprolol or flecainide.
|
30571258 |
2018 |
Cardiac Arrhythmia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
At the cellular level, ankyrin-B(L1622I/L1622I) myocytes display increased action potential duration and severe arrhythmogenic afterdepolarizations that provide a mechanistic rationale for the arrhythmias.
|
27298202 |
2016 |
Cardiac Arrhythmia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Phenotypic Variability of ANK2 Mutations in Patients With Inherited Primary Arrhythmia Syndromes.
|
27784853 |
2016 |
Cardiac Arrhythmia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Rare functional variants of ankyrin-B have been implicated in human disease, including hereditary cardiac arrhythmia and type 2 diabetes (T2D).
|
26168218 |
2015 |
Cardiac Arrhythmia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
βII spectrin recruits ankyrin-B to the cardiac dyad, and a novel human mutation in the ankyrin-B gene disrupts the ankyrin-B/βII spectrin interaction, leading to severe human arrhythmia phenotypes.
|
25632041 |
2015 |
Cardiac Arrhythmia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These findings illustrate the complexity of the molecular components involved in human arrhythmia and define regulatory elements of the ankyrin-B pathway in pathophysiology.
|
23059182 |
2012 |
Cardiac Arrhythmia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, loss of ankyrin-B in atrial myocytes results in decreased Ca(v)1.3 expression, membrane localization, and function sufficient to produce shortened atrial action potentials and arrhythmias.
|
21859974 |
2011 |
Cardiac Arrhythmia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We performed a comprehensive screen of ANK2 in populations (control, congenital arrhythmia, drug-induced long-QT syndrome) of different ethnicities to discover unidentified ANK2 variants.
|
17242276 |
2007 |
Cardiac Arrhythmia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Ankyrin-B variants associated with severe human arrhythmia phenotypes (eg E1425G, V1516D, R1788W) were rare in the general population.
|
17940615 |
2007 |
Cardiac Arrhythmia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Human ANK2 mutations are associated with "ankyrin-B syndrome" (an atypical arrhythmia syndrome with risk of sudden cardiac death).
|
16800854 |
2006 |
Cardiac Arrhythmia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mutations in ANK2-encoded ankyrin-B underlie long QT syndrome type 4 (LQT4) and various other dysrhythmia phenotypes.
|
16253912 |
2005 |
Cardiac Arrhythmia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Among these LQT models, the LQT3 and LQT4 mice exhibit spontaneous or exercise-induced life-threatening arrhythmias characteristics of long-QT patients.
|
15176421 |
2004 |
Cardiac Arrhythmia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
A loss-of-function mutation of ankyrin-B identified in an extended kindred causes a dominantly inherited cardiac arrhythmia, initially described as type 4 long QT syndrome.
|
15178757 |
2004 |
Cardiac Arrhythmia
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Ankyrin-B mutation also leads to altered Ca2+ signalling in adult cardiomyocytes that results in extrasystoles, and provides a rationale for the arrhythmia.
|
12571597 |
2003 |
Cardiac Arrhythmia
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
Ankyrin-B mutation also leads to altered Ca2+ signalling in adult cardiomyocytes that results in extrasystoles, and provides a rationale for the arrhythmia.
|
12571597 |
2003 |